PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
R&D reduction while TRVN shows 26.37% growth. Joel Greenblatt would examine competitive risk.
-21.01%
G&A reduction while TRVN shows 8.20% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Operating expenses reduction while TRVN shows 15.71% growth. Joel Greenblatt would examine advantage.
-10.76%
Total costs reduction while TRVN shows 15.71% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
10.97%
EBITDA growth 1.25-1.5x TRVN's 8.46%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Other expenses growth less than half of TRVN's 3122.22%. David Dodd would verify if advantage is sustainable.
11.35%
Pre-tax income growth 1.25-1.5x TRVN's 9.25%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense growth 1.25-1.5x TRVN's 209.34%. Martin Whitman would scrutinize strategy.
11.35%
Net income growth 1.25-1.5x TRVN's 9.25%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS growth exceeding 1.5x TRVN's 12.41%. David Dodd would verify competitive advantages.
31.72%
Diluted EPS growth exceeding 1.5x TRVN's 12.41%. David Dodd would verify competitive advantages.
29.31%
Share count reduction below 50% of TRVN's 3.96%. Michael Burry would check for concerns.
29.44%
Diluted share reduction below 50% of TRVN's 3.96%. Michael Burry would check for concerns.